Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.56
Percentage change -1.47	%

Peers: AMRX ANIP ARDX ASRT ASND EYPT HRTX LXRX PCRX PTGX

| Held by: IJR IWM VTI CALF IWO SPSM IJT VXF PJP PBE

Index	RUT	P/E	36.33	EPS (ttm)	1.04	Insider Own	4.17%	Shs Outstand	31.55M	Perf Week	-0.63%
Market Cap	1.19B	Forward P/E	4.51	EPS next Y	8.34	Insider Trans	-13.57%	Shs Float	30.19M	Perf Month	21.74%
Enterprise Value	1.90B	PEG	8.67	EPS next Q	2.05	Inst Own	115.58%	Short Float	13.96%	Perf Quarter	26.15%
Income	36.27M	P/S	1.68	EPS this Y	20.73%	Inst Trans	-1.80%	Short Ratio	13.20	Perf Half Y	26.66%
Sales	707.01M	P/B	5.11	EPS next Y	7.09%	ROA	2.74%	Short Interest	4.22M	Perf YTD	31.34%
Book/sh	7.36	P/C	4.90	EPS next 5Y	4.19%	ROE	16.16%	52W High	42.29 -11.01%	Perf Year	6.06%
Cash/sh	7.68	P/FCF	5.87	EPS past 3/5Y	0.01% -	ROIC	3.24%	52W Low	23.23 61.99%	Perf 3Y	100.16%
Dividend Est.	-	EV/EBITDA	5.19	Sales past 3/5Y	31.63% 16.31%	Gross Margin	56.69%	Volatility	2.11% 3.39%	Perf 5Y	106.19%
Dividend TTM	-	EV/Sales	2.68	EPS Y/Y TTM	-63.00%	Oper. Margin	21.73%	ATR (14)	1.17	Perf 10Y	107.67%
Dividend Ex-Date	-	Quick Ratio	1.10	Sales Y/Y TTM	22.61%	Profit Margin	5.13%	RSI (14)	68.90	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	1.18	EPS Q/Q	-34.00%	SMA20	12.01%	Beta	0.61	Target Price	44.60
Payout	0.00%	Debt/Eq	4.10	Sales Q/Q	29.41%	SMA50	18.11%	Rel Volume	1.41	Prev Close	38.19
Employees	357	LT Debt/Eq	3.81	Earnings	Aug 07 BMO	SMA200	23.90%	Avg Volume	319.43K	Price	37.63
IPO	May 07, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.92% 3.93%	Trades		Volume	445,615	Change	-1.47%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-10-25	Upgrade	Needham	Hold → Buy	$46
Jul-30-24	Upgrade	H.C. Wainwright	Neutral → Buy	$47
Jun-07-24	Upgrade	Jefferies	Hold → Buy	$41 → $44
May-10-24	Downgrade	Piper Sandler	Overweight → Neutral	$39
May-10-24	Downgrade	Needham	Buy → Hold
Jan-04-24	Downgrade	Jefferies	Buy → Hold	$30 → $37
Aug-25-23	Reiterated	Needham	Buy	$35 → $36
May-02-23	Resumed	Jefferies	Buy	$30
Aug-08-22	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-15-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$18 → $26
Aug-06-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-11-21	Reiterated	H.C. Wainwright	Buy	$29 → $33
Jul-14-20	Initiated	BWS Financial	Sell	$8
May-27-20	Initiated	Guggenheim	Neutral
Feb-19-20	Resumed	Jefferies	Buy	$43
Oct-30-19	Reiterated	Needham	Buy	$33 → $25
May-03-19	Resumed	H.C. Wainwright	Buy	$23
Apr-12-19	Resumed	Janney	Buy	$29
Mar-20-19	Initiated	SunTrust	Hold	$22
Jan-16-19	Reiterated	Needham	Buy	$35 → $33

Show Previous Ratings

Aug-14-25 01:34AM	The 5 Most Interesting Analyst Questions From Collegium Pharmaceutical's Q2 Earnings Call (StockStory)
Aug-12-25 03:25AM	COLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure (StockStory)
Aug-11-25 09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 02:53PM	Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q2 Expectations, Stock Jumps 10.2% (StockStory) +10.72%
09:30AM	Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics (Zacks)
08:50AM	Loading…
08:50AM	Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:49AM	Collegium Pharmaceutical: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook (GlobeNewswire)
Aug-06-25 05:50PM	Inotiv, Inc. (NOTV) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 11:11PM	Collegium Pharmaceutical (COLL) Q2 Earnings: What To Expect (StockStory)
10:00AM	Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-31-25 10:00AM	Collegium Pharmaceutical (COLL) Q2 Earnings Preview: What's in the Cards? (Zacks)
Jul-28-25 12:01AM	3 Reasons to Avoid COLL and 1 Stock to Buy Instead (StockStory)
Jul-25-25 09:55AM	Wall Street Analysts See a 33.91% Upside in Collegium Pharmaceutical (COLL): Can the Stock Really Move This High? (Zacks)
09:40AM	Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? (Zacks)
08:00AM	Loading…
Jul-24-25 08:00AM	Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-10-25 04:09PM	5 Hot Stocks With Summer Buybacks You Can Cash In On (MarketBeat)
Jul-07-25 08:00AM	Collegium Announces $150 Million Share Repurchase Program (GlobeNewswire)
Jul-01-25 02:42AM	Collegium Pharmaceutical Announces Share Repurchase Program Worth $25 Million (Insider Monkey)
Jun-30-25 06:24AM	5 Insightful Analyst Questions From Collegium Pharmaceutical's Q1 Earnings Call (StockStory)
Jun-10-25 04:40AM	COLL Q1 Earnings Call: ADHD Portfolio Drives Growth, Management Details Capital Deployment Priorities (StockStory)
Jun-05-25 11:31PM	Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers (StockStory)
May-19-25 04:01PM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-12-25 08:05AM	Collegium Announces $25 Million Accelerated Share Repurchase Program (GlobeNewswire)
May-09-25 03:42AM	Collegium Pharmaceutical Inc (COLL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com) +5.94%
May-08-25 05:30PM	Compared to Estimates, Collegium Pharmaceutical (COLL) Q1 Earnings: A Look at Key Metrics (Zacks)
05:15PM	Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates (Zacks)
04:11PM	Collegium Pharmaceutical: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-07-25 06:15PM	ElectroCore, Inc. (ECOR) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
05:20PM	Loading…
05:20PM	Collegium Pharmaceutical Q1 2025 Earnings Preview (Seeking Alpha)
10:28AM	Collegium Pharmaceutical Inc (COLL) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-01-25 10:01AM	Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-28-25 12:12PM	Indivior: Trying To Break Addiction (Seeking Alpha)
09:01AM	3 Healthcare Stocks That Concern Us (StockStory)
Apr-24-25 08:00AM	Collegium to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
03:55AM	Third Avenue Small Cap Value Fund Q1 2025 Commentary (Seeking Alpha)
Apr-23-25 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks)
Apr-16-25 02:41PM	IYH: Healthcare Dashboard For April (Seeking Alpha)
Apr-14-25 05:11AM	2 Reasons to Watch COLL and 1 to Stay Cautious (StockStory)
Apr-02-25 05:05AM	A Look Back at Branded Pharmaceuticals Stocks' Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack (StockStory)
Apr-01-25 08:00AM	Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-25 08:00AM	Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting (GlobeNewswire)
Mar-26-25 07:00AM	Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board (GlobeNewswire)
Mar-18-25 03:22PM	Teva Pharmaceutical Stock Scores RS Rating Upgrade (Investor's Business Daily)
Mar-17-25 07:00AM	Collegium Announces Updates to its Board of Directors and Executive Leadership Team (GlobeNewswire)
Mar-10-25 06:57PM	Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care (GlobeNewswire)
Mar-04-25 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-01-25 06:45AM	Is Collegium Pharmaceutical, Inc. (COLL) the Best Small Cap Pharma Stocks to Buy Now? (Insider Monkey)
Feb-28-25 07:05AM	Q4 2024 Collegium Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
02:37AM	Collegium Pharmaceutical Inc (COLL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-27-25 07:00PM	Collegium Pharmaceutical (COLL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:45PM	Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates (Zacks)
04:52PM	Collegium Pharmaceutical: Q4 Earnings Snapshot (Associated Press Finance)
04:28PM	Collegium Pharmaceuticals (NASDAQ:COLL) Q4 Sales Top Estimates, Stock Jumps 14.1% (StockStory)
04:01PM	Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
Feb-26-25 09:15AM	Seeking Clues to Collegium Pharmaceutical (COLL) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
08:12AM	Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect (StockStory)
07:53AM	What To Expect From Collegium Pharmaceutical Inc (COLL) Q4 2024 Earnings (GuruFocus.com)
Feb-13-25 08:00AM	Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Feb-05-25 08:00AM	Collegium Appoints Nancy S. Lurker to its Board of Directors (GlobeNewswire)
Jan-09-25 08:30AM	Collegium Pharmaceutical Unveils 2025 Financial Projections (TipRanks)
Jan-08-25 08:00AM	Collegium Provides 2025 Financial Guidance and Business Update (GlobeNewswire) +14.41%
Nov-13-24 09:40AM	Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now? (Zacks)
Nov-12-24 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-08-24 10:03AM	Collegium Pharmaceutical Inc (COLL) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -7.35%
08:34AM	Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock? (Zacks)
Nov-07-24 06:30PM	Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings (Zacks)
05:35PM	Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates (Zacks)
04:34PM	Collegium Pharmaceutical: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Collegium Reports Record Third Quarter 2024 Financial Results (GlobeNewswire)
04:01PM	Collegium Appoints Vikram Karnani as Chief Executive Officer (GlobeNewswire)
Nov-06-24 07:25AM	What To Expect From Collegium Pharmaceutical Inc (COLL) Q3 2024 Earnings (GuruFocus.com)
Oct-31-24 10:01AM	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-28-24 09:40AM	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? (Zacks)
Oct-24-24 08:00AM	Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-11-24 09:40AM	Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? (Zacks)
Oct-09-24 05:55PM	Collegium Pharmaceutical Inc (COLL) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Oct-04-24 02:37PM	Breakouts Boost These Three Stocks To All-Time Highs (Investor's Business Daily)
Sep-25-24 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks)
Sep-09-24 12:00PM	Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why (Zacks)
09:40AM	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? (Zacks)
Sep-07-24 01:28AM	Insider Sale: EVP and General Counsel Shirley Kuhlmann Sells 20,225 Shares of Collegium ... (GuruFocus.com)
Sep-04-24 08:00AM	Collegium Completes Acquisition of Ironshore Therapeutics (GlobeNewswire)
Aug-30-24 08:00AM	Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-28-24 08:00AM	Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024 (GlobeNewswire)
Aug-08-24 09:59PM	COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
06:00PM	Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:25PM	Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates (Zacks)
04:20PM	Collegium Pharmaceutical: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Collegium Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-07-24 09:15AM	Unveiling Collegium Pharmaceutical (COLL) Q2 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Aug-01-24 10:01AM	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy? (Zacks)
06:30AM	Compass Pathways announces second quarter 2024 financial results and business highlights (GlobeNewswire)
Jul-31-24 06:53AM	Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock? (Zacks)
Jul-30-24 09:33AM	Collegium buys Ironshore for $525m and enter ADHD market (Pharmaceutical Technology) +10.63%
Jul-29-24 06:00AM	Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology (GlobeNewswire)
Jul-25-24 08:00AM	Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jun-24-24 12:56PM	7 Biotech Stocks to Buy on the Dip: June 2024 (InvestorPlace)
Jun-13-24 08:00AM	Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise (GlobeNewswire)

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SANTINI GINO	Director	Aug 15 '25	Option Exercise	13.45	15,000	201,750	100,447	Aug 19 05:10 PM
SANTINI GINO	Director	Aug 15 '25	Sale	37.19	5,405	201,018	95,042	Aug 19 05:10 PM
Dreyer Scott	Officer	Aug 18 '25	Proposed Sale	38.21	16,389	626,170		Aug 18 04:50 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 13 '25	Option Exercise	21.34	4,861	103,734	108,474	Aug 15 05:08 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 13 '25	Sale	38.03	4,861	184,881	103,613	Aug 15 05:08 PM
Rubric Capital Management LP	10% Owner	Aug 13 '25	Sale	37.85	25,000	946,250	3,132,743	Aug 15 04:12 PM
SANTINI GINO	Director	Aug 15 '25	Proposed Sale	37.19	5,405	201,019		Aug 15 12:34 PM
Dreyer Scott	Officer	Aug 13 '25	Proposed Sale	38.03	4,861	184,881		Aug 13 04:31 PM
Freund John Gordon	Director	Aug 08 '25	Sale	34.36	11,659	400,641	23,129	Aug 12 05:18 PM
Heffernan Michael Thomas	Former Director	Jul 09 '25	Proposed Sale	32.17	10,328	332,269		Jul 09 04:10 PM
Heffernan Michael Thomas	Former Director	Jul 08 '25	Proposed Sale	31.38	790	24,792		Jul 08 04:19 PM
Heffernan Michael Thomas	Former Director	Jul 07 '25	Proposed Sale	31.25	14,210	444,062		Jul 07 04:43 PM
Heffernan Michael Thomas	Former Director	Jul 02 '25	Proposed Sale	30.30	25,000	757,380		Jul 02 04:50 PM
Melincoff Gwen A	Former Director	Jul 02 '25	Proposed Sale	30.29	47,082	1,425,971		Jul 02 04:35 PM
Freund John Gordon	Director	Jun 09 '25	Option Exercise	13.45	15,000	201,750	77,259	Jun 11 05:04 PM
Freund John Gordon	Director	Jun 09 '25	Sale	30.62	6,601	202,149	70,658	Jun 11 05:04 PM
Freund John Gordon	Director	Jun 09 '25	Proposed Sale	30.62	6,601	202,148		Jun 09 01:02 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 21 '25	Sale	30.03	6,396	192,069	156,667	Mar 24 05:06 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 20 '25	Sale	30.00	1,206	36,181	163,063	Mar 24 05:06 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 21 '25	Sale	30.03	18,881	566,983	103,613	Mar 24 05:05 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 20 '25	Sale	30.00	1,927	57,811	122,494	Mar 24 05:05 PM
Tupper Colleen	Officer	Mar 21 '25	Proposed Sale	30.03	6,396	192,069		Mar 21 04:35 PM
Dreyer Scott	Officer	Mar 21 '25	Proposed Sale	30.03	18,881	566,984		Mar 21 04:21 PM
Tupper Colleen	Officer	Mar 20 '25	Proposed Sale	30.00	1,206	36,181		Mar 20 04:32 PM
Kuhlmann Shirley R.	Former Officer	Mar 20 '25	Proposed Sale	29.65	40,494	1,200,632		Mar 20 04:19 PM
Dreyer Scott	Officer	Mar 20 '25	Proposed Sale	30.00	1,927	57,811		Mar 20 04:17 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 14 '25	Sale	30.00	977	29,313	164,269	Mar 18 05:35 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 14 '25	Sale	30.00	2,255	67,661	124,421	Mar 18 05:34 PM
Tupper Colleen	Officer	Mar 14 '25	Proposed Sale	30.00	977	29,313		Mar 14 04:06 PM
Dreyer Scott	Officer	Mar 14 '25	Proposed Sale	30.00	2,255	67,661		Mar 14 03:55 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 06 '25	Sale	30.00	15,387	461,672	126,676	Mar 13 04:50 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 11 '25	Sale	30.01	10,445	313,413	165,246	Mar 13 04:49 PM
Tupper Colleen	Officer	Mar 11 '25	Proposed Sale	30.01	10,445	313,413		Mar 11 04:16 PM
Dreyer Scott	Officer	Mar 11 '25	Proposed Sale	30.00	15,387	461,672		Mar 11 04:08 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 06 '25	Sale	30.00	1,949	58,470	177,195	Mar 10 04:02 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 07 '25	Sale	30.00	1,504	45,121	175,691	Mar 10 04:02 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 06 '25	Sale	30.00	3,295	98,854	144,411	Mar 10 04:01 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 07 '25	Sale	30.00	2,348	70,446	142,063	Mar 10 04:01 PM
Dreyer Scott	Officer	Mar 07 '25	Proposed Sale	30.00	2,348	70,446		Mar 07 04:21 PM
Tupper Colleen	Officer	Mar 07 '25	Proposed Sale	30.00	1,504	45,121		Mar 07 04:13 PM
Kuhlmann Shirley R.	EVP and General Counsel	Mar 04 '25	Option Exercise	24.03	40,000	961,200	194,204	Mar 06 06:48 PM
Kuhlmann Shirley R.	EVP and General Counsel	Mar 04 '25	Sale	28.08	40,000	1,123,160	154,204	Mar 06 06:48 PM
Kuhlmann Shirley R.	EVP and General Counsel	Mar 06 '25	Sale	28.50	26,067	742,946	108,137	Mar 06 06:48 PM
Kuhlmann Shirley R.	EVP and General Counsel	Mar 05 '25	Sale	28.03	20,000	560,528	134,204	Mar 06 06:48 PM
Tupper Colleen	Officer	Mar 06 '25	Proposed Sale	30.00	1,949	58,470		Mar 06 04:43 PM
Dreyer Scott	Officer	Mar 06 '25	Proposed Sale	30.00	3,295	98,854		Mar 06 04:31 PM
Kuhlmann Shirley R.	Officer	Mar 06 '25	Proposed Sale	28.50	26,067	742,946		Mar 06 10:42 AM
Kuhlmann Shirley R.	Officer	Mar 05 '25	Proposed Sale	28.03	20,000	560,528		Mar 05 03:03 PM
Kuhlmann Shirley R.	Officer	Mar 04 '25	Proposed Sale	28.08	40,000	1,123,160		Mar 04 04:16 PM
Kuhlmann Shirley R.	EVP and General Counsel	Jan 10 '25	Option Exercise	21.34	27,500	586,850	146,684	Jan 14 04:12 PM
Kuhlmann Shirley R.	EVP and General Counsel	Jan 10 '25	Sale	33.04	27,500	908,628	119,184	Jan 14 04:12 PM
Kuhlmann Shirley R.	Officer	Jan 10 '25	Proposed Sale	33.04	27,500	908,628		Jan 10 04:14 PM
Smith Thomas B	EVP and Chief Medical Officer	Sep 13 '24	Sale	36.62	9,593	351,320	53,816	Sep 17 04:32 PM
Smith Thomas B	Officer	Sep 13 '24	Proposed Sale	36.98	373	13,794		Sep 13 10:39 AM
Smith Thomas B	Officer	Sep 13 '24	Proposed Sale	36.61	9,220	337,516		Sep 13 10:06 AM
Kuhlmann Shirley R.	EVP and General Counsel	Sep 05 '24	Sale	38.30	19,248	737,198	120,161	Sep 06 05:52 PM
Kuhlmann Shirley R.	EVP and General Counsel	Sep 06 '24	Sale	37.46	977	36,594	119,184	Sep 06 05:52 PM
Kuhlmann Shirley R.	Officer	Sep 06 '24	Proposed Sale	37.46	977	36,594		Sep 06 11:53 AM
Kuhlmann Shirley R.	Officer	Sep 05 '24	Proposed Sale	38.30	19,248	737,197		Sep 05 04:47 PM

Open in Screener

HRTX

Heron Therapeutics Inc

Aug 19 • 04:00PM ET

1.29

Dollar change -0.01
Percentage change -0.77	%

Healthcare • Biotechnology • USA • NASD

HRTX Heron Therapeutics Inc daily Stock Chart

Peers: JNJ PFE ABBV MRK BMY GILD LLY AMGN VRTX REGN

| Held by: VTI IWM VXF IWN VTWO SCHA VHT IWC ITOT IWO

Index	RUT	P/E	-	EPS (ttm)	-0.01	Insider Own	1.00%	Shs Outstand	153.25M	Perf Week	-1.53%
Market Cap	197.75M	Forward P/E	21.50	EPS next Y	0.06	Insider Trans	270.97%	Shs Float	151.75M	Perf Month	-32.81%
Enterprise Value	333.86M	PEG	-	EPS next Q	-0.01	Inst Own	88.73%	Short Float	23.23%	Perf Quarter	-32.81%
Income	-0.93M	P/S	1.32	EPS this Y	66.67%	Inst Trans	10.30%	Short Ratio	22.46	Perf Half Y	-25.00%
Sales	149.69M	P/B	-	EPS next Y	300.00%	ROA	-0.41%	Short Interest	35.26M	Perf YTD	-15.69%
Book/sh	-0.18	P/C	4.87	EPS next 5Y	-	ROE	-	52W High	2.68 -51.87%	Perf Year	-33.85%
Cash/sh	0.27	P/FCF	-	EPS past 3/5Y	65.87% 48.68%	ROIC	-	52W Low	1.04 24.04%	Perf 3Y	-75.66%
Dividend Est.	-	EV/EBITDA	88.79	Sales past 3/5Y	18.67% -0.23%	Gross Margin	74.61%	Volatility	6.41% 6.49%	Perf 5Y	-91.81%
Dividend TTM	-	EV/Sales	2.23	EPS Y/Y TTM	98.13%	Oper. Margin	0.96%	ATR (14)	0.12	Perf 10Y	-95.70%
Dividend Ex-Date	-	Quick Ratio	0.53	Sales Y/Y TTM	9.78%	Profit Margin	-0.62%	RSI (14)	26.97	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.82	EPS Q/Q	74.42%	SMA20	-20.57%	Beta	1.24	Target Price	4.75
Payout	-	Debt/Eq	-	Sales Q/Q	3.26%	SMA50	-32.04%	Rel Volume	0.90	Prev Close	1.30
Employees	122	LT Debt/Eq	-	Earnings	Aug 08 BMO	SMA200	-30.51%	Avg Volume	1.57M	Price	1.29
IPO	Aug 26, 1987	Option/Short	Yes / Yes	EPS/Sales Surpr.	-100.00% -2.30%	Trades		Volume	1,404,691	Change	-0.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-09-25	Initiated	H.C. Wainwright	Buy	$6
Jun-13-24	Initiated	Rodman & Renshaw	Buy	$7
Apr-23-24	Initiated	CapitalOne	Overweight	$6
Mar-13-24	Reiterated	Needham	Buy	$4 → $5
May-27-20	Initiated	Guggenheim	Buy	$24
Feb-20-20	Reiterated	Needham	Buy	$50 → $48
Jan-16-19	Reiterated	Needham	Buy	$66 → $64
Apr-05-18	Initiated	Evercore ISI	Outperform	$56
Mar-19-18	Reiterated	Mizuho	Buy	$28 → $35
Mar-01-18	Reiterated	Needham	Buy	$28 → $30
Jan-03-18	Initiated	Leerink Partners	Outperform	$22
Sep-27-17	Initiated	Northland Capital	Outperform	$40
Feb-27-17	Initiated	Needham	Buy	$28
Oct-26-16	Initiated	Aegis Capital	Buy
Sep-06-16	Resumed	Lake Street	Buy	$45
May-03-16	Initiated	Cantor Fitzgerald	Buy
Dec-10-15	Initiated	Lake Street	Buy	$45
Sep-23-15	Reiterated	Leerink Partners	Outperform	$38 → $57
Sep-02-15	Initiated	BofA/Merrill	Buy	$46
Aug-03-15	Reiterated	Brean Capital	Buy	$40 → $45

Show Previous Ratings

Aug-15-25 07:45AM	Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value (PR Newswire)
Aug-09-25 03:05AM	Heron Therapeutics Inc (HRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Aug-08-25 09:30AM	Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -28.26%
08:55AM	Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:52AM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:45AM	Loading…
07:45AM	Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress (PR Newswire)
07:45AM	Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile (PR Newswire)
06:00AM	Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025 (PR Newswire)
Jul-28-25 09:42PM	Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 (PR Newswire)
Jul-07-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jul-04-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
May-07-25 03:38PM	Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025 (Seeking Alpha) -6.61%
03:04AM	Heron Therapeutics Inc (HRTX) Q1 2025 Earnings Call Highlights: Record EBITDA and Significant ... (GuruFocus.com)
May-06-25 09:30AM	Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics (Zacks) +13.62%
08:55AM	Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates (Zacks)
07:53AM	Loading…
07:53AM	Heron Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:45AM	Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
07:30AM	Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI and APONVIE Patent Litigations (PR Newswire)
May-05-25 10:33AM	MTD Q1 Earnings Top Estimates, Sales Decline Y/Y, Shares Rise (Zacks) -7.79%
May-01-25 10:01AM	Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-29-25 10:01AM	Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-28-25 06:55PM	Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer (PR Newswire)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks)
Apr-23-25 09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Apr-22-25 04:05PM	Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025 (PR Newswire) +11.40%
10:15AM	Best Momentum Stocks to Buy for April 22nd (Zacks)
09:40AM	Are Medical Stocks Lagging Encompass Health (EHC) This Year? (Zacks)
07:24AM	New Strong Buy Stocks for April 22nd (Zacks)
Mar-26-25 03:57PM	Is Heron Therapeutics, Inc. (HRTX) The Hot Biotech Stock Under $5? (InsiderMonkey)
02:08AM	Loading…
Feb-28-25 02:08AM	Heron Therapeutics Inc (HRTX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) +20.49%
12:56AM	Q4 2024 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-25 09:30AM	Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +19.88%
07:54AM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:45AM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Feb-13-25 04:20PM	Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025 (PR Newswire) +7.88%
Dec-23-24 04:05PM	Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina (PR Newswire)
Dec-03-24 04:36PM	U.S. District Court Upholds Validity of CINVANTI Patents (PR Newswire) +38.98%
Nov-13-24 02:05AM	Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights (GuruFocus.com) -5.47%
Nov-12-24 10:00AM	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) -30.43%
09:10AM	Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:06AM	Heron Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:55AM	Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance (PR Newswire)
Nov-07-24 09:15AM	Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Nov-04-24 05:00PM	Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors (PR Newswire)
Oct-29-24 04:05PM	Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 (PR Newswire) -7.33%
Oct-10-24 04:08PM	Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI, SUSTOL, and APONVIE as Alternatives During the Potential Shortage of Intravenous Fluids (PR Newswire)
Sep-25-24 08:00AM	Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire)
Sep-03-24 08:00AM	Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer (PR Newswire) -10.36%
Aug-06-24 07:30PM	Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -25.09%
06:45PM	Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:36PM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance (PR Newswire)
Jul-30-24 04:05PM	Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 (PR Newswire) +5.69%
Jul-15-24 08:00AM	Heron Therapeutics Announces the Inclusion of ZYNRELEF as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System (PR Newswire)
Jul-11-24 12:00PM	Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +8.88%
Jul-02-24 08:00AM	Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire) -21.04%
May-29-24 08:05AM	Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire)
May-21-24 12:00PM	What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now? (Zacks)
May-08-24 12:30PM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:10AM	Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Call Transcript Highlights: Significant ... (GuruFocus.com)
May-07-24 12:54PM	HRTX Stock Earnings: Heron Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:34AM	Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Overview: Surpasses Revenue Estimates (GuruFocus.com)
09:30AM	Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:05AM	Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:06AM	Heron Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Apr-30-24 10:01AM	Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know (Zacks) -7.20%
Apr-24-24 08:00AM	Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 (PR Newswire) -5.36%
Apr-11-24 04:05PM	Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City (PR Newswire) +7.69%
Mar-28-24 04:05PM	Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-13-24 09:19AM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call Transcript (Insider Monkey) +27.54%
07:04AM	Q4 2023 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-12-24 06:00PM	Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics (Zacks)
05:33PM	Heron Therapeutics Inc (HRTX) Exceeds Full-Year Revenue Guidance for 2023 (GuruFocus.com)
04:34PM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Mar-07-24 09:15AM	Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Feb-28-24 08:00AM	Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 (PR Newswire)
Feb-23-24 11:56AM	12 Best Rising Penny Stocks To Buy (Insider Monkey)
Feb-06-24 12:00PM	All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy (Zacks)
Jan-25-24 06:44AM	Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion (Zacks)
Jan-24-24 01:47PM	Heron Therapeutics' Non-Opioid, Post-Operative Pain Drug Approved For Use In Additional Orthopedic, Soft Tissue Procedures - FDA Gives Nod (Benzinga) +18.86%
Jan-23-24 08:00PM	Heron Therapeutics Announces FDA Approval of ZYNRELEF Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures (PR Newswire) -5.98%
Jan-15-24 04:51PM	The 3 Most Undervalued Biotech Stocks to Buy in January (InvestorPlace)
09:55AM	Heron Therapeutics (HRTX) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Jan-07-24 05:00PM	Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain (PR Newswire)
Dec-10-23 12:23PM	Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master (Associated Press Finance)
Dec-06-23 11:55AM	13 Hot Penny Stocks To Buy According to Hedge Funds (Insider Monkey)
Nov-28-23 07:33PM	Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth (InvestorPlace) -7.95% +7.00%
Nov-15-23 10:17AM	Heron Therapeutics Inc (HRTX) Raises 2023 Sales Guidance and Projects Positive EBITDA in 2024 (GuruFocus.com) +59.26%
08:51AM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:46AM	Q3 2023 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 06:00PM	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
04:17PM	Heron Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance (PR Newswire)
Nov-07-23 04:05PM	Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023 (PR Newswire) +6.88% -9.20%
Aug-24-23 09:29AM	11 Best Long-Term Penny Stocks to Buy Now (Insider Monkey)
Aug-15-23 01:30PM	Heron Therapeutics (HRTX) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) +10.93%
12:48PM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2023 Earnings Call Transcript (Insider Monkey)

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in Cary, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rubric Capital Management LP	10% Owner	Aug 08 '25	Buy	1.50	2,387,225	3,580,838	29,100,728	Aug 12 06:00 PM
Morgan Adam	Director	Aug 08 '25	Buy	1.50	1,766,546	2,649,819	8,753,290	Aug 12 05:02 PM

Dollar change -8.73
Percentage change -2.32	%

Peers: EXC AEP DUK D NRG SO PEG ED FE EIX

| Held by: VTI VB VBR VXF UTES VPU SCHA IWR SCHM BAI

Index	-	P/E	105.12	EPS (ttm)	3.50	Insider Own	1.79%	Shs Outstand	45.66M	Perf Week	-3.27%
Market Cap	16.82B	Forward P/E	18.57	EPS next Y	19.83	Insider Trans	-32.15%	Shs Float	44.87M	Perf Month	18.71%
Enterprise Value	19.74B	PEG	12.37	EPS next Q	3.33	Inst Own	100.17%	Short Float	5.58%	Perf Quarter	53.21%
Income	187.00M	P/S	4.57	EPS this Y	-63.37%	Inst Trans	-7.48%	Short Ratio	2.22	Perf Half Y	47.05%
Sales	3.68B	P/B	13.49	EPS next Y	206.36%	ROA	2.90%	Short Interest	2.50M	Perf YTD	82.74%
Book/sh	27.29	P/C	124.59	EPS next 5Y	8.50%	ROE	9.95%	52W High	394.07 -6.57%	Perf Year	171.42%
Cash/sh	2.95	P/FCF	-	EPS past 3/5Y	- -	ROIC	4.43%	52W Low	131.31 180.37%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	9.94	Sales past 3/5Y	-22.69% -	Gross Margin	65.38%	Volatility	3.38% 3.89%	Perf 5Y	-
Dividend TTM	-	EV/Sales	5.37	EPS Y/Y TTM	-74.67%	Oper. Margin	43.24%	ATR (14)	14.51	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.34	Sales Y/Y TTM	125.17%	Profit Margin	5.09%	RSI (14)	59.60	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	1.84	EPS Q/Q	-80.21%	SMA20	-0.66%	Beta	1.60	Target Price	398.66
Payout	0.00%	Debt/Eq	2.46	Sales Q/Q	122.62%	SMA50	15.75%	Rel Volume	0.72	Prev Close	376.89
Employees	1894	LT Debt/Eq	2.39	Earnings	Aug 07 BMO	SMA200	52.84%	Avg Volume	1.13M	Price	368.16
IPO	Jun 02, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	244.62% 60.72%	Trades		Volume	811,290	Change	-2.32%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-13-25	Initiated	Raymond James	Outperform	$314
Mar-12-25	Initiated	Morgan Stanley	Overweight	$243
Feb-21-25	Initiated	Evercore ISI	Outperform
Feb-03-25	Initiated	BofA Securities	Buy	$253
Dec-04-24	Initiated	Daiwa Securities	Buy	$248
Oct-17-24	Initiated	JP Morgan	Overweight	$268
Sep-26-24	Initiated	RBC Capital Mkts	Outperform	$233
Sep-18-24	Initiated	UBS	Buy	$197
Sep-13-24	Initiated	Jefferies	Buy	$226
Sep-04-24	Initiated	Guggenheim	Buy	$169
Aug-21-24	Initiated	Barclays	Overweight	$178

Show Previous Ratings

Aug-19-25 12:00PM	Talen Energy Corporation (TLN) Is Up 0.84% in One Week: What You Should Know (Zacks)
Aug-18-25 10:00AM	Best Momentum Stock to Buy for August 18th (Zacks)
Aug-14-25 08:12PM	Kenvue attracts share purchase by activist investor Sachem Head (Reuters)
07:19AM	UBS assesses which themes should be more or less favored (Investing.com)
Aug-13-25 02:21PM	Three Stocks Morgan Stanley Recommends for Playing the Nuclear Renaissance' (Investopedia)
12:06PM	Loading…
12:06PM	Nuclear Stocks Are Hot. This One Just Got a Big Target-Price Increase. (Barrons.com)
07:23AM	Here's What Boosted Talen Energy Corporation (TLN) in Q2 (Insider Monkey)
Aug-07-25 11:22PM	Talen Energy Posts Solid Q2, Expands Amazon Deal and Makes $3.5B Gas Plant Play (Oilprice.com)
07:15AM	Talen Energy Corporation (TLN) Q2 Earnings and Revenues Surpass Estimates (Zacks)
06:15AM	Talen Energy: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Talen Energy Reports Second Quarter 2025 Results, Reaffirms 2025 Guidance (GlobeNewswire)
Aug-06-25 09:40AM	Is Galp Energia (GLPEY) Stock Outpacing Its Oils-Energy Peers This Year? (Zacks)
Aug-04-25 10:00AM	Earnings Preview: Kolibri Global Energy Inc. (KGEI) Q2 Earnings Expected to Decline (Zacks)
Jul-31-25 10:00AM	Analysts Estimate Talen Energy Corporation (TLN) to Report a Decline in Earnings: What to Look Out for (Zacks)
07:50AM	TC Energy (TRP) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:01PM	Loading…
Jul-30-25 04:01PM	Appointment of Director to the Board (GlobeNewswire)
Jul-29-25 02:06AM	UBS Raises Talen Target to $431 After $3.5B Power Plant Buy (Insider Monkey)
Jul-24-25 10:30PM	Talen Energy (TLN) Gains Following Strategic Acquisition (Insider Monkey)
03:52AM	Zacks Investment Ideas feature highlights: Range Nuclear Renaissance Index ETF, GE Vernova, Talen, Amazon and Rolls-Royce (Zacks)
Jul-23-25 04:33PM	Buy GE Vernova and Soaring AI-Boosted Nuclear Energy Stocks? (Zacks) +8.18%
04:22PM	GE Vernova Jumps On Q2. That's Not Why Energy Stocks Are Rallying. (Investor's Business Daily)
03:41PM	Oklo and Liberty Energy Stocks Get a Boost from 'Strategic Alliance' Announcement (Barrons.com)
10:08AM	Talen Energy, Constellation, and Vistra Stock Are on the Rise. What's Lifting Shares. (Barrons.com)
09:55AM	Is Oklo Stock's Sky-High Valuation Justified or Simply Driven by Hype? (Zacks)
09:17AM	Talen Energy Stock, Constellation, and Vistra Are on the Rise. What's Lifting the Shares. (Barrons.com)
09:07AM	AI Boom Leads to Record US Grid Costs, Call for New Plants (Bloomberg)
08:54AM	GE Vernova Jumps On Q2. That's Not Why Energy Stock Are Rallying. (Investor's Business Daily)
Jul-22-25 04:53PM	Talen Energy Reports PJM Auction Results for the 2026/2027 Planning Year (GlobeNewswire)
02:40PM	The U.S. Aims To Be An AI Data Center Powerhouse. Trump And Big Tech See This State As The Epicenter. (Investor's Business Daily)
Jul-21-25 06:30AM	Biggest US Power Sale to Offer Glimpse of AIs Cost to Consumers (Bloomberg) -5.63%
04:32PM	Loading…
Jul-18-25 04:32PM	These Stocks Moved the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More (Barrons.com) +24.48%
02:24PM	These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More (Barrons.com)
01:38PM	Top Stock Movers Now: Invesco, Talen Energy, Norfolk Southern, and More (Investopedia)
12:43PM	Talen Energy Stock Soars Over 20% on Purchase of 2 Plants in AI Power Move (Investopedia)
11:22AM	Talen Energy Soars On $3.5 Billion Deal To 'Enhance' Data Center Load; S&P 500 Rivals Jump (Investor's Business Daily)
10:09AM	Talen Stock Soars on Plant Purchases. Why the Market Is Excited About the Nuclear Plays Bet on Gas. (Barrons.com)
09:56AM	Talen Energy, 3M outlook, SLB earnings: Trending Tickers (Yahoo Finance Video)
07:57AM	Talen Stock Surges on Plant Purchases. Why the Market Is Excited About the Nuclear Play's Bet on Gas. (Barrons.com)
06:51AM	Talen Energy Stock Surges on Plant Purchases. It's Not Just a Nuclear Play. (Barrons.com)
05:15AM	Talen Energy to acquire two CCGT plants in US for $3.5bn (Power Technology)
03:00AM	Data Centers Aren't Just a U.S. Trend. These Stocks Could Benefit from Europe's Power Surge. (Barrons.com)
Jul-17-25 05:00PM	Talen Energy to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
04:01PM	Talen Energy Expands and Enhances Portfolio with Best-in-Class CCGT Acquisitions in PJM (GlobeNewswire)
Jul-15-25 10:10AM	How OKLO is Positioning Itself in the Emerging Nuclear Energy Market (Zacks)
Jul-10-25 07:58AM	Will Talen Energy Corporation (TLN) Benefit from Continued AI Development? (Insider Monkey)
Jul-09-25 06:30AM	AI investing: Why power producers are the next winners (Yahoo Finance Video)
Jul-08-25 11:40AM	AMRC vs. TLN: Which Stock Is the Better Value Option? (Zacks)
Jul-04-25 12:10PM	How Oklo Plans to Power the AI & Cloud Boom With Nuclear Energy (Zacks)
Jul-02-25 08:30AM	GE Vernova Wins Puerto Rico Turbine Deal: What Lies Ahead for the Stock? (Zacks)
Jun-25-25 04:30PM	Raymond James Initiates Coverage of Talen Energy Corporation (TLN) Stock, Gives Outperform (Insider Monkey)
10:25AM	Big Money Inflows Electrify Talen Energy (FX Empire)
Jun-23-25 12:03PM	New York State wants more nuclear power in a big way (TechCrunch)
07:44AM	2 Nuclear Energy Stocks in Focus Amid Multi-Decade Data Center Deal (Zacks)
Jun-16-25 10:30PM	Talen Energy Secures Nuclear Energy Deal with Amazon (Insider Monkey)
01:01PM	Talen Energy Corp (TLN) Is A "Good One," Says Jim Cramer (Insider Monkey)
06:20AM	Should iShares Morningstar Small-Cap Value ETF (ISCV) Be on Your Investing Radar? (Zacks)
Jun-12-25 11:46AM	Oklo Stock Dips. It's Selling $400 Million of Shares After a Record High. (Barrons.com)
Jun-11-25 05:29PM	How Amazon's Nuclear Deal Could Solve a Touchy Political Problem (Barrons.com) +7.73%
04:51PM	Vinson & Elkins Represents Talen Energy in Agreement to Power Amazon Data Centers (Exec Edge)
11:34AM	Talen Energy and Amazon, Urban Outfitters: Trending Tickers (Yahoo Finance Video)
10:04AM	Talen Energy Stock Rises as Nuclear Partnership With Amazon Is Expanded (Barrons.com)
06:00AM	Talen Energy Expands Nuclear Energy Relationship with Amazon (GlobeNewswire)
Jun-04-25 11:57AM	Insurance Software Maker Guidewire Pops On Earnings Report. Asana Plunges. (Investor's Business Daily)
10:40AM	S&P 500 Nuclear Stocks Receive Price Target Hikes Following 20-Year Meta Deal (Investor's Business Daily)
08:23AM	Futures Rise Ahead Of Jobs Data; CrowdStrike Plummets, S&P 500 Eyes Key Level (Live Coverage) (Investor's Business Daily)
06:44AM	Dow Jones Futures Rise, CrowdStrike Leads Early Movers; Market Tops Resistance (Investor's Business Daily)
Jun-03-25 06:54PM	Wells Fargo Asset Cap Lifted By Federal Reserve After Seven Years; Stock Rises In Buy Zone (Investor's Business Daily)
06:04PM	Stock Market Extends Gains As S&P 500 Scores A Breakout And Nasdaq Eyes 20,000; CoreWeave Jumps (Investor's Business Daily)
04:58PM	Dow Jones Futures: Market Tops Key Levels, Nvidia In Buy Zone; Tesla CEO Elon Musk Rips Trump Budget 'Abomination' (Investor's Business Daily)
11:19AM	GEV's Turbines to Power Saudi Gas Plant: How to Play the Stock (Zacks)
10:49AM	Stock Market Today: Dow Jones Flat After Win Streak; Meta Deal Lifts Stocks In This Group (Live Coverage) (Investor's Business Daily)
May-15-25 08:15AM	Five Point Infrastructure Announces the Formation of PowerBridge With a $1 Billion Equity Commitment, to Develop and Build Gigawatt-Scale Powered Data Center Campuses in North America (Business Wire)
May-13-25 05:39PM	Is Talen Energy (TLN) the Best Young Stock to Buy According to Hedge Funds? (Insider Monkey)
May-10-25 03:33AM	Talen Energy Corporation (TLN): Among the Best Energy Stocks to Buy Right Now (Insider Monkey)
May-09-25 04:30PM	Utility stocks outperform S&P 500 with 'no signs of recession' in power demand (Yahoo Finance) +5.09%
May-08-25 07:55AM	GE Vernova Boosts its FLEXINVERTER Platform: Should You Buy the Stock Now? (Zacks)
07:00AM	Talen Energy Reports First Quarter 2025 Results, Affirms and Narrows 2025 Guidance (GlobeNewswire)
May-07-25 06:20PM	Ormat Technologies (ORA) Surpasses Q1 Earnings Estimates (Zacks)
11:42AM	GEVO Set to Report Q1 Earnings: What Can an Investor Expect? (Zacks)
May-06-25 09:05AM	Cheniere Energy to Report Q1 Earnings: What's in the Offing? (Zacks) +5.60%
07:25AM	Enlight Renewable Energy Ltd. (ENLT) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
May-05-25 05:35AM	Canadian Natural to Report Q1 Earnings: What's in the Offing? (Zacks)
May-01-25 06:00PM	FERC Approves Reliability Must Run Settlement Agreement for Units at Talen Energy's Brandon Shores and H.A. Wagner Power Plants (GlobeNewswire)
Apr-30-25 11:32PM	Tracking AMG's Yacktman Asset Management Portfolio - Q1 2025 Update (Seeking Alpha)
Apr-27-25 11:13PM	Is Talen Energy Corporation (TLN) the Best Nuclear Energy Stock to Buy According to Billionaires? (Insider Monkey)
Apr-25-25 03:47AM	Talen Energy Benefits From Growing Power Demand (Seeking Alpha)
Apr-23-25 07:50AM	Alluvial Capital Management Q1 2025 Letter To Partners (Seeking Alpha)
Apr-18-25 11:40AM	EE vs. TLN: Which Stock Should Value Investors Buy Now? (Zacks)
Apr-17-25 11:34PM	Talen Energy Corporation (TLN): Among the Best Utility Stocks to Buy According to Analysts (Insider Monkey) -5.94%
07:00AM	Talen Energy to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-09-25 08:57AM	GE Vernova to Boost Germany's Wind Power: Should You Buy the Stock Now? (Zacks) +11.39%
Apr-03-25 11:24AM	Liberation Day: Thoughts And Opportunities (Seeking Alpha) -14.12%
Apr-02-25 09:00AM	Here's What Lifted Talen Energy Corporation (TLN) in Q4 (Insider Monkey)
Mar-28-25 11:40AM	KGEI or TLN: Which Is the Better Value Stock Right Now? (Zacks)
Mar-27-25 04:10PM	Joseph Nigro Appointed to Eos Energy Enterprises Board of Directors (GlobeNewswire)
Mar-25-25 08:59PM	Tracking Lone Pine Capital Portfolio - Q4 2024 Update (SeekingAlpha) -6.72%
Mar-22-25 06:35PM	Is Talen Energy (TLN) The Best Alternative Energy Stock to Buy Now? (Insider Monkey)
Mar-20-25 12:34PM	Is Talen Energy Corporation (NASDAQ:TLN) the Best Nuclear Power Stock to Buy Now? (InsiderMonkey)
Mar-14-25 10:10AM	Trump Trade: Trump family holds talks for stake in Binance U.S. arm (TipRanks)
Mar-12-25 04:18PM	Nuclear Energy Stock Talen Soars Amid Bullish Initiation (Investor's Business Daily) +12.76%

Talen Energy Corp. engages in the operation of power infrastructure. It produces and sells electricity, capacity, and ancillary services into wholesale power markets through its subsidiaries. The company was founded on July 2, 2014 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rubric Capital Management LP	10% Owner	Jun 27 '25	Sale	296.04	178,000	52,695,684	5,734,970	Jun 27 06:45 PM
Rubric Capital Management LP	10% Owner	Jun 25 '25	Sale	291.29	108,313	31,550,492	6,015,187	Jun 27 06:45 PM
Rubric Capital Management LP	10% Owner	Jun 26 '25	Sale	291.98	102,217	29,845,813	5,912,970	Jun 27 06:45 PM
Horton Anthony R	Director	Mar 06 '25	Buy	190.59	1,000	190,588	1,000	Mar 10 04:08 PM
Rubric Capital Management LP	10% Owner	Dec 13 '24	Sale	204.35	4,893,507	999,999,900	6,475,107	Dec 16 04:00 PM

COLL

Collegium Pharmaceutical Inc

HRTX

Heron Therapeutics Inc

TLN

Talen Energy Corp

Upgrade your FINVIZ experience